Brainstorm Cell Therapeutics Inc., incorporated on November 15, 2006, is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn.The Company’s NurOwn technology is based on a differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells, marrow stromal cells secreting neurotrophic factors (MSC-NTF cells), capable of releasing several neurotrophic factors, including Glial-derived neurotrophic factor (GDNF), Brain-derived neurotrophic factor (BDNF), Vascular endothelial growth factor (VEGF) and Hepatocyte growth factor (HGF), which are critical for the growth, survival and differentiation of developing neurons. GDNF is the potent survival factors known for peripheral neurons. VEGF and HGF have important neuro-protective effects in ALS.
|Bank Name||Brainstorm Cell Therapeutics Inc.|
|Industry||Biotechnology: Biological Products|
|CEO||Mr. Chaim Lebovits|